新天药业控股股东拟减持股份，或影响公司股价
关键要点梳理
- 控股股东减持计划：贵阳新天药业（证券代码：002873）控股股东上海新天智药生物技术有限公司（以下简称“新天智药”）计划自本公告披露之日起15个交易日后的3个月内（2026年5月29日至2026年8月28日），通过大宗交易与集中竞价方式合计减持不超过7,050,000股，占公司剔除回购股份后总股本的2.9962%。
- 减持方式与比例：其中，大宗交易减持不超过4,700,000股（1.9975%），集中竞价减持不超过2,350,000股（0.9987%）。
- 减持股份来源：本次减持股份为公司首次公开发行前股份及历年权益分派所获得的股份。
- 减持价格：减持价格不低于公司首次公开发行股票除权除息后的发行价4.97元/股，最终价格以市场价为准。
- 减持目的：本次减持所得资金将主要用于归还部分质押借款，降低股权质押风险，提升控股股东及公司整体风险应对能力。
- 现有持股情况：截至公告日，新天智药持有公司68,435,566股，占剔除回购股份后总股本的29.0847%。
- 承诺履行情况：新天智药此前关于股份锁定、减持价格、减持数量等承诺已全部履行完毕。
- 法律合规：本次减持计划符合相关法律法规要求，如《证券法》、《上市公司股东减持股份管理办法》等。
- 减持计划不确定性：控股股东将根据市场及公司股价情况决定是否实施减持，存在不确定性。
- 对公司影响：本次减持有助于降低公司股权质押风险，增强股权稳定性，不会导致公司控制权变更，也不会对治理结构和持续经营产生影响。
对投资者的重要提示与潜在影响
- 股东减持是市场关注的敏感事件，短期内可能对公司股价造成一定压力，投资者需重点关注后续减持进展。
- 减持目的明确、合规，为降低质押风险，显示控股股东稳健经营的意愿，但亦提醒部分投资者对公司股东信心的解读。
- 减持区间明确，最低减持价设定为4.97元/股，有一定保护作用，但若市场价格低于该价位则减持不会执行。
- 减持规模接近3%，为近年来较大规模，若市场承接力不足，易引发短期股价波动。
- 公司控制权及经营稳定性未受影响，但未来如有进一步减持需持续关注。
详细信息披露
- 公司总股本：244,103,806股，截至2026年5月6日，公司回购专用账户持有8,806,030股，剔除后总股本为235,297,776股。
- 控股股东持股比例：29.08%（剔除回购股份）。
- 拟减持数量及方式：
- 大宗交易：4,700,000股，占总股本1.9975%。
- 集中竞价：2,350,000股，占总股本0.9987%。
- 减持期间：2026年5月29日至2026年8月28日，窗口期不减持。
- 减持价格：不低于4.97元/股（除权除息后发行价）。如期间有分红、送股等事项，将调整减持价格和数量。
- 承诺履行情况：控股股东历次锁定、减持限制、收益归属等承诺均已如期履行。
- 法律合规声明：减持计划未违反任何法律法规，公司将持续督促控股股东履行信息披露义务。
- 风险提示：本次减持计划具有不确定性，最终实施情况需以实际进展为准。
结论
新天药业控股股东大比例减持计划，资金用途明确，合规合法，短期或对股价产生一定波动影响。建议投资者密切关注减持进展及后续公告，理性判断投资风险。
免责声明：本文基于公司公告公开信息整理，仅作为投资参考，不构成任何投资建议。投资有风险，入市需谨慎。
English Version
Xintian Pharmaceutical: Major Shareholder Plans Significant Share Reduction, Potential Price Impact
Key Highlights
- Share Reduction Plan: Guiyang Xintian Pharmaceutical’s (Stock Code: 002873) controlling shareholder, Shanghai Xintian Zhiyao Biotechnology Co., Ltd. (“Xintian Zhiyao”), plans to reduce its holdings by up to 7,050,000 shares (2.9962% of total share capital after buyback deduction) via block trade and central auction between May 29, 2026 and August 28, 2026.
- Reduction Method & Proportion: Block trade up to 4,700,000 shares (1.9975%), central auction up to 2,350,000 shares (0.9987%).
- Source of Shares: Pre-IPO shares and those obtained through past equity distributions.
- Reduction Price: Not lower than the ex-rights IPO price of RMB 4.97/share, final price to be determined by market.
- Purpose: Funds raised will repay pledged loans and lower pledge risks, enhancing risk resilience for both shareholder and the company.
- Current Holding: As of the announcement, Xintian Zhiyao holds 68,435,566 shares (29.0847% of share capital after buyback deduction).
- Commitment Fulfillment: All previous lockup, price, and reduction commitments by the shareholder have been honored.
- Legal Compliance: The reduction plan complies with all relevant regulations, including the Securities Law and Shareholder Share Reduction Management Measures.
- Uncertainty: The shareholder will decide on execution based on market and share price, so plan implementation is not guaranteed.
- Impact on Company: The reduction is intended to stabilize shareholding structure; no change of control or governance impact is expected.
Important Notes & Potential Price Impact for Investors
- Shareholder reduction is often a sensitive event, which could put short-term pressure on the share price. Investors should closely monitor subsequent reduction progress.
- Reduction purpose is clear and compliant, mainly to lower pledge risks, showing prudent management intent, but some investors may question shareholder confidence.
- Minimum reduction price is set at RMB 4.97/share, providing downside protection; reduction will not proceed if market price is lower.
- The reduction scale is nearly 3%, a relatively large figure in recent years. Insufficient market absorption could trigger price volatility.
- No change to company control or stable operations, but further reductions in the future should be watched.
Detailed Disclosure
- Total share capital: 244,103,806 shares; after buyback, 235,297,776 shares.
- Shareholder holding: 29.08% (post-buyback).
- Reduction quantities and methods:
- Block trade: 4,700,000 shares (1.9975%).
- Central auction: 2,350,000 shares (0.9987%).
- Reduction period: May 29, 2026 to August 28, 2026 (no reduction during window period).
- Reduction price: Not lower than RMB 4.97/share (ex-rights IPO price). Adjustments will be made for any dividends, bonus shares, etc.
- Commitment fulfillment: All lockup, reduction limit, and benefit allocation commitments have been fulfilled.
- Legal compliance: No violation of any laws or regulations; the company will supervise and ensure information disclosure.
- Risk warning: The reduction plan is not certain and subject to actual execution.
Conclusion
Xintian Pharmaceutical’s major shareholder’s planned share reduction, with a clear and compliant purpose, may cause short-term share price fluctuations. Investors are advised to closely follow future updates and assess risks rationally.
Disclaimer: This article is based on publicly available company announcements and is for reference only. It does not constitute investment advice. Investment involves risks; please exercise caution when entering the market.
